Key facts
Mechanism of action
Melanocortin receptor agonist (MC4R primarily). FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Off-label use for male erectile dysfunction and libido. Acts centrally on desire pathways.
Standard dosing
Typical clinical use: 1.75 mg SC 45 minutes before sexual activity (Vyleesi label). Dosing varies by indication and provider protocol; this is reference-only and not a prescribing recommendation. PT-141 requires a prescription from a licensed clinician.
Regulatory status & pharmacy pathway
FDA-approved (Vyleesi); off-label compounded use for other indications. FDA limits which peptides a pharmacy may compound; check this page’s dated FDA status notice before assuming a peptide is legally available. Ask which licensed pharmacy fills the prescription and check that pharmacy’s license with your state board of pharmacy.
U.S. telehealth providers prescribing PT-141
The most commonly cited U.S. telehealth providers for PT-141 are Defy Medical, Marek Health, Hone Health, Maximus, and PeterMD —, whose offerings for this peptide we have not verified (see the FDA status notice above). See the full provider directory for complete profiles.
Trade-offs to know
PT-141 carries the trade-offs common to all compounded peptide therapeutics: not FDA-approved, cash-pay only, no in-network insurance coverage, and pharmacy-quality variation between providers. Choose a prescriber that names its pharmacy, explains its follow-up schedule and states the regulatory status of what it prescribes.
Related peptides in the sexual health category
Editorial team
Researched by Dr. Parmis (Medical Researcher, Western University of Health Sciences); medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC).